vascular disrupting agent


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.

vascular disrupting agent

Any of a class of medications used to destroy the blood supply of malignant tumors.
See also: agent
References in periodicals archive ?
Vascular disrupting agents are a newer class of agents that selectively attack tumor vasculature like anti-angiogenesis agents, but differ in molecular mechanism and affect established tumor blood vessels.
NPI-2358 is a vascular disrupting agent currently in clinical development for the treatment of cancer by Nereus.
NPI-2358, a novel vascular disrupting agent, is being evaluated in patients with solid tumors and lymphomas, and the second-generation proteasome inhibitor NPI-0052 is being developed in patients with solid tumors, lymphomas, leukemias and multiple myeloma.
Other subjects examined include chemokines in angiogenesis, small-molecule vascular disrupting agents in cancer therapy, and the role of imaging in the clinical development of antiangiogenic agents.
OXiGENE believes that ZYBRESTAT is poised to become the first therapeutic product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs).
Pipeline Analysis & Forecasts: Angiogenesis Inhibitors and Vascular Disrupting Agents
The oral activity of CYT997 is a key advantage over most other vascular disrupting agents which are administered intravenously.
MedPredict's panel also reviews recent advances in other mechanistic approaches to treatment, including angiogenesis/VEGF, vascular disrupting agents, anthracyclines, TRAIL / DR4 / DR5, Bcl-2/Bcl-xL, survivin, cyclin dependent kinase, cMET, EGFR (T790M), antifolate, HDAC / epigenetics, Hedgehog, HSP90, IGF-1, MAGE-A3, MEK, microtubule, apoptosis, kinesin/EG5, aurora kinase, Polo-like kinase 1, mTOR, PI3/AKT, KRAS, and topoisomerase.
Researchers are pursuing a broad array of mechanistic approaches to treatment, including angiogenics/VEGF, EGFR resistance (T790M, MET), HER2 (ErbB2), antifolate, anti-microtubule, apoptosis, Bcl-2/Bcl-xL, TRAIL, vascular disrupting agents, Ras, Raf, MEK, mTOR, PI3, AKT, IGF-1, HSP90, HDAC, JAK/STAT, MAGE-A3, CDK, Aurora Kinase, and anticoagulation.

Full browser ?